Skip to main
OCUL

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix is a promising company, with a strong focus on developing innovative therapies for ophthalmic diseases. The company's pipeline, with products such as Dextenza and Axpaxli, shows potential for strong financial growth in the future. While there are some risks involved, including heavy reliance on the success of Axpaxli and market competition, the company's management team remains confident in their strategy and approach. Overall, Ocular Therapeutix presents a positive outlook for investors looking for potential growth in the biopharmaceutical market.

Bears say

Ocular Therapeutix is in an impressive position for such a young biotechnology company, with promising pipeline products including Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT. However, the long-term success of these products hinges on the approval and commercialization of its lead asset AXPAXLI, which is not expected until 2027. Furthermore, there is competition from established anti-VEGF products, and potential intellectual property risks add to the company's overall uncertainty. With a majority of its earnings potential coming from assets that are not yet commercial, Ocular Therapeutix's financial risks are also a concern. Due to these factors, a negative outlook is warranted for Ocular Therapeutix's stock.

Ocular Therapeutix (OCUL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Ocular Therapeutix (OCUL) has a Strong Buy consensus rating as of Aug 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.